Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

May 04, 2017

Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

Apr 27, 2017

Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

Apr 27, 2017

Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer

Apr 24, 2017

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

Apr 05, 2017

Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

Apr 04, 2017

Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

Mar 30, 2017

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

Mar 20, 2017

Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

Mar 16, 2017

Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

Mar 14, 2017
RSS
  • Prev
    • 1...
    • 62
    • 63
    • 64
    • 65
    • 66
    • 67
    • 68
    • 69
    • 70
    • 71
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap